Prolactin is Involved in the Systemic Inflammatory Response in Myocardial Infarction

Abstract

Prolactin may contribute to an atherogenic phenotype. Furthermore, previous studies have shown that prolactin levels increase in situations of acute stress and inflammation. We therefore aimed to investigate the relationship between prolactin, acute stress and inflammation in patients with myocardial infarction. We performed a case-control study in 40 patients with myocardial infarction and 39 controls, aged 41–84 years. Blood for assessment of prolactin and high sensitive C-reactive protein (hsCRP) was drawn at inclusion, that is, during the acute phase of the event, and 2–3 weeks later. Unexpectedly, prolactin levels at inclusion did not differ between cases and controls (7.0 ng/ml and 6.0 ng/ml, respectively, p=0.28). 2–3 weeks later prolactin levels in cases had not decreased. However, univariate regression analysis indicated that hsCRP is associated with prolactin levels (regression coefficient β 0.11; [95% CI 0.01; 0.21]; p=0.03) in cases during the acute phase of myocardial infarction. Our findings may suggest that prolactin is involved in the systemic inflammatory response, which takes place during myocardial infarction; however, this association may not be strong enough to induce higher prolactin levels in patients with myocardial infarction.

Key words

myocardial infarction - prolactin - inflammation

References

• 1 van Zaane B, Reuwer AQ, Buller HR, Kastelein JJ, Gerdes VE, Twickler MT. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?.  Semin Thromb Hemost. 2009;  35 478-487
• 2 Horseman ND. Prolactin and mammary gland development.  J Mammary Gland Biol Neoplasia. 1999;  4 79-88
• 3 Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.  Clin Endocrinol (Oxf). 2009 December 18;  [Epub ahead of print]
• 4 Pelkonen R, Nikkila EA, Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma.  Clin Endocrinol (Oxf). 1982;  16 383-390
• 5 Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.  Clin Endocrinol (Oxf). 2006;  64 366-370
• 6 Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women.  Eur J Endocrinol. 2003;  149 187-193
• 7 Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP, Papamichael C. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors.  Hypertension. 2009;  54 98-105
• 8 Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, Daniel WG, Lohmann T, Garlichs CD. Increased prolactin in acute coronary syndromes as putative Co-activator of ADP-stimulated P-selectin expression.  Horm Metab Res. 2006;  38 767-772
• 9 Gordon EM, Hellerstein HK, Ratnoff OD, Arafah BM, Yamashita TS. Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction.  J Lab Clin Med. 1987;  109 409-413
• 10 La Follette L, Gordon EM, Mazur CA, Ratnoff OD, Yamashita TS. Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction.  J Lab Clin Med. 198;  110 318-321
• 11 Webster Marketon JI, Glaser R. Stress hormones and immune function.  Cell Immunol. 2008;  252 16-26
• 12 Ferrari R, Ceconi C, Rodella A, Harris P, Visioli O. Hormonal response in untreated myocardial infarction.  Cardioscience. 1990;  1 55-60
• 13 Horrobin DF, McNeilly AS, Jackson FS, Reid DS, Tynan M, Nassar BA, Manku MS, Elliott K. Letter: Prolactin and myocardial infarction.  Lancet. 1973;  2 1261
• 14 Weizman R, Eldar M, Hod H, Eshkol A, Rabinowitz B, Tyano S, Neufeld HN. Effects of uncomplicated acute myocardial infarction on biochemical parameters of stress and sexual function.  Psychosomatics. 1991;  32 275-279
• 15 Chikanza IC, Grossman AB. Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop.  Baillieres Clin Rheumatol. 1996;  10 199-225
• 16 Kelley KW, Weigent DA, Kooijman R. Protein hormones and immunity.  Brain Behav Immun. 2007;  21 384-392
• 17 Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van De Werf FJ, Weintraub WS, Mitchell KR, Morrisson SL, Brindis RG, Anderson HV, Cannom DS, Chitwood WR, Cigarroa JE, Collins-Nakai RL, Ellis SG, Gibbons RJ, Grover FL, Heidenreich PA, Khandheria BK, Knoebel SB, Krumholz HL, Malenka DJ, Mark DB, Mckay CR, Passamani ER, Radford MJ, Riner RN, Schwartz JB, Shaw RE, Shemin RJ, Van Fossen DB, Verrier ED, Watkins MW, Phoubandith DR, Furnelli T. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee).  J Am Coll Cardiol. 2001;  38 2114-2130
• 18 Nokin J, Vekemans M, L’Hermite M, Robyn C. Circadian periodicity of serum prolactin concentration in man.  Br Med J. 1972;  3 561-562
• 19 Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ, Boekholdt SM, Khaw KT. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women.  Circ Cardiovasc Genet. 2009;  2 389-395

Correspondence